Other OTC - Delayed Quote • USD
Veradigm Inc. (MDRX)
At close: April 19 at 3:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 3 | 3 |
| Avg. Estimate | 0.28 | 0.44 | 0.82 | 0.77 |
| Low Estimate | 0.23 | 0.17 | 0.79 | 0.43 |
| High Estimate | 0.34 | 0.97 | 0.86 | 1 |
| Year Ago EPS | 0.79 | 0.13 | 1.43 | 0.82 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 4 | 4 |
| Avg. Estimate | 167.46M | 149.77M | 614.59M | 630.71M |
| Low Estimate | 166.5M | 146.4M | 612M | 611.73M |
| High Estimate | 168.06M | 154M | 619.3M | 649M |
| Year Ago Sales | 391.7M | 142.7M | 1.5B | 614.59M |
| Sales Growth (year/est) | -57.20% | 5.00% | -59.10% | 2.60% |
Earnings History
| CURRENCY IN USD | 12/31/2021 | 3/31/2022 | 6/30/2022 | 9/30/2022 |
|---|---|---|---|---|
| EPS Est. | 0.32 | 0.21 | 0.15 | 0.19 |
| EPS Actual | 0.79 | 0.13 | 0.18 | 0.23 |
| Difference | 0.47 | -0.08 | 0.03 | 0.04 |
| Surprise % | 146.90% | -38.10% | 20.00% | 21.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 0.28 | 0.44 | 0.82 | 0.77 |
| 7 Days Ago | 0.28 | 0.44 | 0.82 | 0.94 |
| 30 Days Ago | 0.28 | 0.44 | 0.82 | 0.94 |
| 60 Days Ago | 0.3 | 0.29 | 0.84 | 0.88 |
| 90 Days Ago | 0.3 | 0.29 | 0.85 | 0.88 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | MDRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -64.60% | -- | -- | 1.60% |
| Next Qtr. | 238.50% | -- | -- | 10.50% |
| Current Year | -42.70% | -- | -- | 5.20% |
| Next Year | -6.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -18.32% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 9.87% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Deutsche Bank: Buy to Hold | 3/19/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 1/19/2024 |
| Initiated | Barclays: Equal-Weight | 1/3/2024 |
| Reiterates | Stephens & Co.: Equal-Weight to Equal-Weight | 11/14/2023 |
| Reiterates | Stephens & Co.: Equal-Weight to Equal-Weight | 10/10/2023 |
| Downgrade | Argus Research: Buy to Hold | 7/6/2023 |
Related Tickers
PINC Premier, Inc.
21.18
+1.88%
AUGX Augmedix, Inc.
2.9900
-0.66%
NRC National Research Corporation
34.03
+3.53%
CCLD CareCloud, Inc.
1.1400
-0.87%
RCM R1 RCM Inc.
11.99
-0.25%
EVH Evolent Health, Inc.
29.51
-0.37%
OMCL Omnicell, Inc.
27.83
+2.13%
OMDA.OL Omda AS
34.00
+1.80%
EUDA EUDA Health Holdings Limited
1.7500
+3.55%
HSTM HealthStream, Inc.
24.84
+3.54%